Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 5:02 pm Unchanged | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 5,305,866 14.000% | 0 (Unchanged) | Filing History |
| 2022-02-11 5:37 pm Sale | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 2,311,455 5.900% | -1,098,669 (-32.22%) | Filing History |
| 2022-02-11 5:37 pm Purchase | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 3,410,124 8.700% | 683,338 (+25.06%) | Filing History |
| 2022-02-11 5:37 pm Sale | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 2,726,786 7.000% | -462,199 (-14.49%) | Filing History |
| 2022-02-11 5:37 pm Purchase | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Inhibrx Inc. INBX | 3,188,985 8.200% | 3,188,985 (New Position) | Filing History |
| 2022-02-09 12:26 pm Sale | 2021-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | LAV Summit Ltd | 151,992 0.400% | -2,321,439 (-93.86%) | Filing History |
| 2021-05-17 4:33 pm Sale | 2021-05-17 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 0 0.000% | -2,129,003 (Position Closed) | Filing History |
| 2021-02-16 4:39 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 2,129,003 5.600% | 2,129,003 (New Position) | Filing History |
| 2021-02-12 7:43 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | VIKING GLOBAL INVESTORS LP | 5,305,866 14.100% | 180,219 (+3.52%) | Filing History |
| 2021-02-12 4:38 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Eckelman Brendan P. | 2,749,953 7.300% | 2,749,953 (New Position) | Filing History |
| 2021-02-12 4:28 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Deveraux Quinn L. | 2,749,953 7.300% | 2,749,953 (New Position) | Filing History |
| 2021-02-12 4:19 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Mark Lappe | 3,149,714 8.400% | 3,149,714 (New Position) | Filing History |
| 2021-02-12 4:14 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Kayyem Jon Faiz | 3,405,809 9.000% | 3,405,809 (New Position) | Filing History |
| 2021-02-09 4:46 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | LAV Summit Ltd | 2,473,431 6.600% | 2,473,431 (New Position) | Filing History |